Cynthia Smith
Director/Board Member chez AKEBIA THERAPEUTICS, INC.
Fortune : 241 587 $ au 31/03/2024
Profil
Cynthia Smith is an Independent Director at Agios Pharmaceuticals, Inc., Akebia Therapeutics, Inc., Spero Therapeutics, Inc., and Protara Therapeutics, Inc. She is also a Director at French-American Foundation.
In the past, she worked as an Executive Director-Healthcare System at Merck & Co., Inc., Chief Commercial Officer at ZS Pharma, Inc., and VP-Market Access & Commercial Development at Affymax, Inc. She also served as an Independent Director at Dicerna Pharmaceuticals, Inc. and Nivalis Therapeutics, Inc. Ms. Smith has an undergraduate degree from The University of North Carolina at Chapel Hill, an MBA from The Wharton School of the University of Pennsylvania, and a graduate degree from Eagleton Institute of Politics.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/06/2023 | 95 233 ( 0,05% ) | 174 276 $ | 31/03/2024 | |
| 11/08/2023 | 2 302 ( 0,00% ) | 67 310 $ | 31/03/2024 | |
| 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
SPERO THERAPEUTICS, INC.
-.--% | 08/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Cynthia Smith
| Sociétés | Poste | Début |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Director/Board Member | 28/08/2018 |
| SPERO THERAPEUTICS, INC. | Director/Board Member | 19/03/2019 |
| PROTARA THERAPEUTICS, INC. | Director/Board Member | 01/01/2021 |
| AGIOS PHARMACEUTICALS, INC. | Director/Board Member | 11/08/2022 |
| French-American Foundation | Director/Board Member | - |
Anciens postes connus de Cynthia Smith
| Sociétés | Poste | Fin |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Director/Board Member | 28/12/2021 |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Director/Board Member | 01/07/2017 |
| ZS PHARMA INC | Corporate Officer/Principal | 01/12/2016 |
| AFFYMAX, INC. | Corporate Officer/Principal | 01/03/2013 |
| ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Cynthia Smith
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Eagleton Institute of Politics | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| AFFYMAX, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| SPERO THERAPEUTICS, INC. | Health Technology |
| PROTARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
| French-American Foundation | |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
